Mesa Verde Venture Partners

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative therapies for patients in hospital settings. Founded in 2013, Zavante is focused on creating treatments that address serious and life-threatening infections, particularly those caused by multi-drug resistant bacteria. One of its key pipeline products is ZOLYD, an investigational injectable antibiotic designed to combat these challenging infections. The company's commitment to improving patient outcomes highlights its role in addressing critical healthcare needs within the hospital environment.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

CalciMedica is a biopharmaceutical company focused on developing therapeutics for inflammatory and autoimmune disorders. It specializes in discovering and developing small molecule drugs that target calcium release-activated calcium channels.

Immix Biopharma, Inc., established in 2014 and headquartered in Los Angeles, California, is a biopharmaceutical company focused on developing innovative therapies for cancer patients, particularly those resistant to conventional treatments like chemotherapy and immunotherapy. The company's pipeline includes Imx-109, a small molecule sensitizing tumors to various therapies; Imx-110 and Imx-111, nanoparticle delivery systems co-loaded with cytotoxic agents and potent synergistic agents; and Imx-004, a humanized antibody targeting an undisclosed tumor-specific antigen. Immix Biopharma's proprietary TME Normalization Technology enables its drug candidates to effectively attack all components of the tumor microenvironment.

MatriSys Bioscience is a clinical-stage biopharmaceutical company focused on developing microbiome therapies for dermatology and skin care markets worldwide. Its lead product, MSB-01, is a topical antimicrobial live bio therapeutic designed to replace deficient bacteria on the skin of atopic dermatitis patients, promoting host defense. The company also offers cosmetic ingredients derived from its proprietary bacterial strains, formulated into cream or gel forms to address various skin concerns such as scaling, flaking, redness, and signs of aging.

NeuraLace Medical, Inc. is a San Diego-based technology company founded in 2016 that specializes in developing a hardware-based neuromodulation platform aimed at managing neuropathic pain. The company focuses on creating a non-invasive interface to deliver sustainable relief from chronic pain, specifically targeting sensory nerve fibers with short bursts of magnetic pulses. This innovative approach offers a non-drug pain management solution that can be implemented in pain clinics, allowing patients to receive treatments while minimizing the risks associated with opioid addiction and surgical interventions. NeuraLace Medical is dedicated to bridging the gap between technology and neurology to enhance the quality of life for individuals suffering from chronic nerve pain.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

Alastin Skincare is a California-based company that specializes in developing innovative and clinically-validated skincare products aimed at enhancing and maintaining healthy skin. Founded in 2015 and located in Carlsbad, the company focuses on creating physician-dispensed products that utilize advanced technology and a proprietary blend of peptides to support the skin's natural regeneration processes. Their offerings include solutions for both ablative and non-ablative rejuvenating procedures, ensuring that dermatologists and plastic surgeons can effectively assist their patients in correcting, protecting, and preserving their skin health. Alastin Skincare emphasizes safety and effectiveness through rigorous clinical testing of its products.

Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and immuno-inflammatory disorders with high unmet medical need. Its lead candidate, EQ001 (Itolizumab), is a first-in-class monoclonal antibody that selectively targets the CD6 immune receptor to downregulate pathogenic effector T cells while preserving regulatory T cells by modulating the CD6-ALCAM signaling pathway. The approach targets a range of immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. Equillium aims to advance its programs through clinical development and may commercialize products independently or through partnerships or strategic transactions to monetize its pipeline.

Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, that focuses on developing therapies utilizing growth hormone-releasing hormone (GHRH) analogs. Since its incorporation in 2012, the company has worked on GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, as well as GHRH agonists designed to aid in the repair of cardiac damage in patients with heart disease. Additionally, Biscayne Pharmaceuticals is developing drugs for refractory epilepsy and drug-resistant cancers, targeting GHRH receptors that stimulate the production of growth hormone necessary for tissue growth and repair. This innovative approach enables the company to address several challenging medical conditions that are often difficult to treat.

Biscayne Neurotherapeutics is a clinical-stage biotechnology company based in Miami, Florida, focused on developing innovative therapies for challenging neurological disorders. The company’s primary product, BIS-001, is a synthetic form of huperzine A, which acts as an acetylcholinesterase inhibitor with significant brain penetration. This unique mechanism of action targets difficult-to-treat conditions, particularly refractory forms of epilepsy, including refractory partial complex seizures and Dravet syndrome in children. Biscayne Neurotherapeutics is supported by an experienced executive team and a network of esteemed scientific advisors specialized in seizure and other central nervous system disorders, positioning the company to make impactful contributions to the field of neurology.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Oncternal Therapeutics is a clinical-stage oncology company focused on developing innovative therapies for a range of cancers, including both rare and common types. The company has a diverse clinical pipeline featuring several promising candidates, including zilovertamab, a humanized monoclonal antibody targeting ROR1, and ONCT-216, a small molecule designed to inhibit ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a CAR-T product targeting ROR1, and ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer. By employing a variety of therapeutic strategies, including antibodies, antibody-drug conjugates, small molecules, and CAR-T technologies, Oncternal Therapeutics seeks to address significant unmet medical needs in oncology through highly targeted treatments.

Independa is a San Diego-based provider of cloud-based software solutions for senior living and home-based care. The company offers a remote care platform that integrates social engagement, reminders for medications and appointments, health monitoring, and activity calendars, along with an enterprise suite that centralizes remote care and well-being tools for senior living communities, short-term rehabilitation facilities, hospitals, and home care organizations. Its products include AnyTV Companion for social connection and caregiving support, CloudCare for modular remote care and wellness, a caregiver dashboard, and Angela, a solution helping seniors maintain independence. The platform connects health devices and home sensors to monitor vital signs and safety, supports broadcast alerts to residents, and enables efficient caregiver workflows through a unified cloud-based service. Independa collaborates with partners, including LG Electronics. Founded in 2009, the company serves organizations seeking technology-enabled independent living and enhanced care coordination.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Elysium Therapeutics is a biotechnology company based in Danville, California, established in 2013. The company specializes in developing innovative opioid pain relievers designed to mitigate the risks associated with oral misuse, abuse, and fatal overdose. Elysium Therapeutics' medications incorporate mechanisms that automatically regulate opioid levels in the bloodstream, preventing them from exceeding safe thresholds. This approach not only aims to significantly reduce the potential for addiction and side effects but also provides healthcare practitioners with effective tools for managing pain in patients.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Biomatrica is a San Diego–based biostability company that develops technologies to stabilize, process, store, and ship biological samples at ambient temperatures, reducing the need for cold chains. The core platform mimics anhydrobiosis to protect DNA, RNA, proteins, cells, and diagnostic assays without degradation, enabling room-temperature storage and shipment. Its product family includes DNAstable for DNA at ambient temperatures, DNAgard chemistries for DNA in tissue, blood, and saliva, RNAstable for RNA, and related solutions for collection, purification, amplification, and storage, along with SampleWare software for sample management and dry storage cabinets for ambient storage. Biomatrica serves life science research, diagnostics development, biobanks, forensics, and sustainability-focused applications, with products sold online and through a global distributor network.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2004, Medipacs specializes in developing non-mechanical infusion pumps designed to deliver a wide range of drugs accurately and comfortably. Their wearable, programmable pumps are used for biologic medications, insulin, hormones, fertility drugs, anti-coagulation drugs, and pain medication.